A Single Dose Study Of PF-04620110 In Overweight And Obese, Otherwise Healthy Volunteers
Status:
Completed
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
PF-04620110 is a novel compound proposed for the treatment of Type 2 diabetes mellitus. The
purpose of this study is to characterize the safety, tolerability, pharmacokinetics and
pharmacodynamics following a single oral dose.